相似文献
1
Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages.
Antimicrob Agents Chemother. 2004 Jun;48(6):2325-30. doi: 10.1128/AAC.48.6.2325-2330.2004.
2
Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu.
Eur Biophys J. 2002 Mar;31(1):26-35. doi: 10.1007/s002490100177.
3
Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
Antimicrob Agents Chemother. 2010 Feb;54(2):835-45. doi: 10.1128/AAC.01308-09. Epub 2009 Dec 7.
4
Lack of effect of recombinant human growth hormone on the in vitro activities of antiretroviral drugs against human immunodeficiency virus type 1.
Antimicrob Agents Chemother. 2004 Jun;48(6):2337-40. doi: 10.1128/AAC.48.6.2337-2340.2004.
5
Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway.
J Infect Dis. 2006 Dec 1;194(11):1547-56. doi: 10.1086/508898. Epub 2006 Oct 19.
6
Effects of vpu start-codon mutations on human immunodeficiency virus type 1 replication in macrophages.
J Gen Virol. 2007 Oct;88(Pt 10):2780-2792. doi: 10.1099/vir.0.83120-0.
7
Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro.
J Gen Virol. 1994 Dec;75 ( Pt 12):3393-400. doi: 10.1099/0022-1317-75-12-3393.
8
Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro.
AIDS Res Hum Retroviruses. 1997 Jul 1;13(10):857-63. doi: 10.1089/aid.1997.13.857.
9
Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR).
Antiviral Res. 2006 Dec;72(3):224-32. doi: 10.1016/j.antiviral.2006.06.008. Epub 2006 Jul 7.
10
Probing interactions of Vpu from HIV-1 with amiloride-based compounds.
Biochim Biophys Acta. 2016 Apr;1858(4):733-9. doi: 10.1016/j.bbamem.2015.12.028. Epub 2015 Dec 23.
引用本文的文献
1
Advances in Viroporin Function and Structure: A Comparative Analysis of Alphavirus 6K with Well-Characterized Viroporins.
Viruses. 2025 Jun 19;17(6):868. doi: 10.3390/v17060868.
2
Hexamethylene amiloride binds the SARS-CoV-2 envelope protein at the protein-lipid interface.
Protein Sci. 2023 Oct;32(10):e4755. doi: 10.1002/pro.4755.
3
Potent NKT cell ligands overcome SARS-CoV-2 immune evasion to mitigate viral pathogenesis in mouse models.
PLoS Pathog. 2023 Mar 24;19(3):e1011240. doi: 10.1371/journal.ppat.1011240. eCollection 2023 Mar.
4
Requirement of a functional ion channel for Sindbis virus glycoprotein transport, CPV-II formation, and efficient virus budding.
PLoS Pathog. 2022 Oct 3;18(10):e1010892. doi: 10.1371/journal.ppat.1010892. eCollection 2022 Oct.
5
Novel Compound Inhibitors of HIV-1 Vpu.
Viruses. 2022 Apr 15;14(4):817. doi: 10.3390/v14040817.
6
Unravelling the Immunomodulatory Effects of Viral Ion Channels, towards the Treatment of Disease.
Viruses. 2021 Oct 27;13(11):2165. doi: 10.3390/v13112165.
7
A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
Br J Pharmacol. 2020 Nov;177(21):4942-4966. doi: 10.1111/bph.15094. Epub 2020 Jul 19.
8
Inhibition of Non Canonical HIV-1 Tat Secretion Through the Cellular Na,K-ATPase Blocks HIV-1 Infection.
EBioMedicine. 2017 Jul;21:170-181. doi: 10.1016/j.ebiom.2017.06.011. Epub 2017 Jun 13.
9
Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication.
Exp Biol Med (Maywood). 2017 Apr;242(8):850-858. doi: 10.1177/1535370217697384. Epub 2017 Jan 1.
10
Ion Channel Activity of Vpu Proteins Is Conserved throughout Evolution of HIV-1 and SIV.
Viruses. 2016 Dec 1;8(12):325. doi: 10.3390/v8120325.
本文引用的文献
1
Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu.
Eur Biophys J. 2002 Mar;31(1):26-35. doi: 10.1007/s002490100177.
2
Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes.
Virology. 1999 Dec 20;265(2):319-29. doi: 10.1006/viro.1999.0047.
3
Potential for the transmission of HIV-1 despite highly active antiretroviral therapy.
N Engl J Med. 1998 Dec 17;339(25):1846-8. doi: 10.1056/NEJM199812173392510.
4
Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells.
J Virol. 1998 Feb;72(2):1270-9. doi: 10.1128/JVI.72.2.1270-1279.1998.
5
Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells.
FEBS Lett. 1996 Nov 25;398(1):12-8. doi: 10.1016/s0014-5793(96)01146-5.
6
Inhibition of human immunodeficiency virus replication in differentiating monocytes by interleukin 10 occurs in parallel with inhibition of cellular RNA expression.
AIDS Res Hum Retroviruses. 1996 Sep 1;12(13):1237-45. doi: 10.1089/aid.1996.12.1237.
7
The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels.
J Virol. 1996 Oct;70(10):7108-15. doi: 10.1128/JVI.70.10.7108-7115.1996.
8
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.
J Virol. 1996 Feb;70(2):809-19. doi: 10.1128/JVI.70.2.809-819.1996.
9
Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7381-5. doi: 10.1073/pnas.90.15.7381.
10
Changes in the host range and growth potential of an HIV-1 clone are conferred by the vpu gene.
Virology. 1993 Jul;195(1):260-4. doi: 10.1006/viro.1993.1370.
Zotero 插件